Journal of Crohn's & colitisHumansCrohn DiseaseInfliximabDeep LearningRetrospective Studies
Development and validation of a novel multimodal deep learning model integrating histopathology, radiology, and clinical data to predict primary non-response to infliximab in patients with Crohn's disease.
Yu Wang, Haipeng Wang, Xiaomin Wu, Xiaoyu Duan, Lihui Zhang, Zishan Liu, Shanshan Xiong, Xuehua Li, Minhu Chen, Ziyin Ye, Yanling Wei, Bingsheng Huang, Ren Mao
Published: 202610.1093/ecco-jcc/jjaf206
Abstract
BACKGROUND AND AIMS: Crohn's disease (CD) is a chronic inflammatory condition of the gastrointestinal tract. While infliximab (IFX) offers significant benefits, 10%-30% of patients remain non-responders initially. This study employs artificial intell…
Preview only. Read the full abstract at the source